Original Article
Brief Report
Improvement in Cardiac Function in the Cardiac Variant of Fabry's Disease with Galactose-Infusion Therapy
N Engl J Med 2001; 345:25-32July 5, 2001
- Article
Fabry's disease is an X-linked inborn error of glycosphingolipid catabolism caused by deficient activity of α-galactosidase A, a lysosomal exoglycosidase.1,2 In males with the classic form of the disease, there is little if any α-galactosidase A activity. As a result, undegraded glycosphingolipids accumulate, particularly in the vascular endothelium. These deposits cause the characteristic angiokeratomas, acroparesthesias, hypohidrosis, and corneal opacities of Fabry's disease. Death in early adulthood in affected persons may be due to vascular disease of the heart, kidney, or brain. These abnormalities are absent in males with the cardiac variant of the disease. Those with the cardiac variant typically present with a mild, late-onset disorder that is primarily limited to the heart, and there is no involvement of the vascular endothelium.1-3 With advancing age, however, cardiac involvement progresses and leads to death.4 All of the previously described patients with the cardiac variant of Fabry's disease had mutations in the α-galactosidase A gene that encoded sufficient residual enzymatic activity to preclude the classic phenotype.1-3,5,6
A recent clinical trial, reported elsewhere in this issue of the Journal, indicated that enzyme-replacement therapy may be safe and effective in patients with classic Fabry's disease.7 Enzyme infusions given every other week cleared the glycosphingolipid deposits in the vascular endothelium of the kidney, heart, and skin. In a finding of relevance to patients with the cardiac variant of the disease, in vitro studies indicated that residual α-galactosidase A activity can be increased by the addition of galactose to the medium of cultured fibroblasts from patients with specific mutations.5,8 Moreover, certain reversible competitive inhibitors of α-galactosidase A, such as 1-deoxygalactonojirimycin, can also increase the activity of the enzyme in cultured fibroblasts from patients with the cardiac variant of the disease.9,10 These findings suggest that treatment with galactose or a nontoxic, reversible competitive enzyme inhibitor may enhance the residual activity of α-galactosidase A, thereby improving the pathological and clinical manifestations of the cardiac variant of the disease.
We describe a 55-year-old man with the cardiac variant of Fabry's disease who had residual α-galactosidase A activity as the result of a missense mutation encoding a substitution of arginine for glycine at position 328 of the enzyme (G328R). He had severe myocardial disease and was a candidate for cardiac transplantation. Therapy with intravenous infusions of galactose, given every other day, was begun, and his condition has been monitored for more than two years.
Case Report
A 55-year-old man presented with angina and dyspnea on mild effort and at rest (New York Heart Association [NYHA] functional class IV). Ten years before presentation, he had received a diagnosis of hypertrophic nonobstructive cardiomyopathy. During the preceding five years, he had had chronic atrial fibrillation and dyspnea with exertion and had been treated with digitalis, diuretics, and angiotensin-converting–enzyme inhibitors. There was no family history of Fabry's disease or hypertrophic cardiomyopathy, although his brother had died suddenly at the age of 50 years. The patient did not have angiokeratomas, acroparesthesias, hypohidrosis, or corneal opacities.
Cardiac auscultation revealed an irregular rhythm, a heart rate of 100 beats per minute, and no pathologic murmurs. The blood pressure was 130/80 mm Hg. Plain-film radiographs of the chest revealed slight enlargement of the heart. An electrocardiogram showed atrial fibrillation (mean ventricular rate, 90 to 100 beats per minute) with left ventricular hypertrophy as well as nonspecific ST-T–wave changes. Holter monitoring revealed an elevated heart rate (150 to 160 beats per minute) during mild exercise and frequent ectopic ventricular beats, with some couplets and triplets (Lown class IVa, where class I is characterized by occasional ventricular ectopic beats and class V by sustained ventricular tachycardia). Two-dimensional Doppler echocardiographic studies showed dilatation of the left atrium (diameter, 50 mm) and left ventricular end-diastolic and end-systolic diameters (68 and 53 mm, respectively), with a moderate reduction in left ventricular contractility (ejection fraction, 33 percent) (Table 1Table 1
Results of Echocardiographic, Hemodynamic, and Cardiac MRI Studies before and during Treatment with Intravenous Galactose.). Both the interventricular septum and the left ventricular posterior free wall were markedly thickened (interventricular septum, 20 mm; left ventricular posterior wall, 16 mm), particularly at the basal septum and apical levels. The right ventricular free wall was moderately hypertrophic. The valves were normal.Spin–echo magnetic resonance imaging (MRI) (Signa Horizon, General Electric Medical Systems, Paris) was performed (repetition time, 25 msec; echo time, 25 msec; matrix, 256 by 160; number of excitations, 3), and cine gradient–echo sequences (repetition time, 30 msec; echo time, 12 msec; flip angle, 35 degrees; matrix, 256 by 128; number of excitations, 3), gated on the horizontal long and short axes, were obtained with a 0.5-T scanner (Vectra, General Electric Medical Systems). Diffuse and symmetric myocardial thickening was evident, particularly in the left midventricular and apical segments and in the right ventricular free wall, with heterogeneous signal intensity. The mean thicknesses of the left ventricular and right ventricular walls at end-diastole were 18 and 10 mm, respectively, and the left ventricular mass was 293 g. All of the midventricular and apical segments were hypokinetic, and the midventricular inferior septum was dyskinetic; the left ventricular diameters at end-diastole were slightly increased, and global left ventricular function was depressed, with an ejection fraction of 31.5 percent (according to Simpson's biplane rule) (Table 1).
Because of his end-stage hypertrophic cardiomyopathy, the patient was considered for cardiac transplantation. Cardiac catheterization, coronary angiography, and left and right ventriculography were performed, and biventricular endomyocardial-biopsy specimens were obtained. The pulmonary and intracavity pressures were elevated. Ventricular angiography revealed moderate dilatation, with diffuse hypertrophy of both ventricles. The left ventricle had a spade-like shape, with moderately impaired contractility (left ventricular ejection fraction, 30 percent). The cardiac index was severely reduced (to 1.69 liters per minute per square meter of body-surface area). Coronary angiography showed that the epicardial coronary arteries were normal. Hematologic values, serum chemical values, and the results of urinalysis were normal; the blood urea nitrogen level was 17 mg per deciliter (6.1 mmol per liter), the serum creatinine level was 1.3 mg per deciliter (115 μmol per liter), and the creatinine clearance was 75 ml per minute.
Methods
Monitoring Procedures
Biopsy specimens were obtained after informed consent had been obtained from the patient and approval had been granted by the local ethics committee. Blood was collected from the coronary sinus for the isolation of lymphocytes and genomic DNA. Left ventricular and right ventricular endomyocardial biopsies were performed for morphologic and biochemical studies. A right ventricular endomyocardial-biopsy specimen (2.8 mg) was obtained through the femoral vein with a 7-French bioptome (502-300L, Cordis, Miami) before and after the first infusions of galactose (3.1 mg). As a control, endomyocardial-biopsy specimens (2.6 to 3.8 mg) were obtained from the papillary muscles of patients with mitral stenosis who were undergoing mitral-valve replacement and who had given their informed consent.
During treatment, the serum galactose, glucose, and creatinine levels and hepatic function were assessed weekly. Electrocardiograms and two-dimensional echocardiograms were obtained monthly, and cardiac MRI was performed three months and two years after the beginning of treatment.
Morphologic Studies
Endomyocardial-biopsy specimens were processed for routine histologic and histochemical analyses and for transmission electron microscopy. For light microscopy, specimens were fixed in 10 percent buffered formalin and embedded in paraffin, and 5-μm sections were stained with hematoxylin and eosin, Miller's elastic Van Gieson stain,11,12 and Masson's trichrome. Frozen sections were stained with periodic acid–Schiff and Sudan black. For transmission electron microscopy, myocardial tissues were fixed in 2 percent glutaraldehyde in 0.1 m phosphate buffer (pH 7.3) and embedded in Epon resin. Ultrathin sections were stained with uranyl acetate and lead hydroxide.
Biochemical and Molecular Studies
Lymphocytes were isolated by gradient centrifugation (Lymphoprep, Nycomed, Oslo, Norway), washed in phosphate-buffered saline, and homogenized in distilled water.13,14 The endomyocardial-biopsy specimens were homogenized in 1 mM citrate–phosphate buffer (pH 4.5) and then centrifuged. The resulting lymphocyte and endomyocardial supernatants were assayed with 4-methylumbelliferyl-α-D-galactoside15 for α-galactosidase A activity (measured as nanomoles per hour per milligram of protein). Genomic DNA was isolated from peripheral blood (Puregene DNA isolation kit, Gentra Systems, Minneapolis), and all of the α-galactosidase A coding regions and adjacent intronic regions were sequenced as previously described.16
Results
Diagnostic Studies
The differential diagnosis of hypertrophic cardiomyopathy in this patient included Fabry's disease, and the typical morphologic changes in the endomyocardial-biopsy specimens (Figure 1AFigure 1
Left Ventricular Endomyocardial-Biopsy Specimens (Hematoxylin and Eosin, ×160)., Figure 2AFigure 2
Transmission Electron Micrographs of Endomyocardial-Biopsy Specimens before Treatment with Intravenous Galactose (Panels A and B) and after Three Months (Panels C and D)., and Figure 2B) suggested this diagnosis. Histologic examination revealed thickened endocardium in both ventricles, with prominent smooth-muscle cells, a finding consistent with the presence of biventricular dilatation. The endomyocardial tissues contained regularly arranged and severely hypertrophic myocardial fibers (often larger than 40 μm in diameter), with large perinuclear vacuoles containing material that stained positive with periodic acid–Schiff and Sudan black. The interstitium was increased in width by areas of fibrosis. The arterioles appeared normal, and there was no evidence of endothelial or smooth-muscle involvement (Figure 1A). Electron microscopy of the myocardial tissue revealed many concentric, lamellar figures in single membrane-bound vesicles (Figure 2A); in cells where these vesicles were infrequent, they were localized preferentially in the perinuclear area of the fibers (Figure 2B). Remarkably, storage inclusions were not seen in the vascular endothelial cells, pericytes, interstitial histiocytes, or fibrocytes.The morphologic diagnosis of Fabry's disease was substantiated by the finding that α-galactosidase A activity in the patient's lymphoblasts was deficient (141 nmol per hour per milligram of protein, or about 2.4 percent of the normal mean [±SD] activity, which is 5890±2130 nmol per hour per milligram of protein). The patient's sister and the sister's three daughters had intermediate levels of lymphocyte α-galactosidase A activity (data not shown). Molecular analyses identified the α-galactosidase A G328R missense mutation in the patient, and these female family members were carriers of the mutation.
Effect of Galactose Infusions
After informed consent had been obtained from the patient, he was initially given a galactose infusion (1 g per kilogram of body weight, administered over a four-hour period) daily for three days. The α-galactosidase A activity in lymphocytes isolated from his coronary-sinus blood was then found to have increased from a mean of 156±31.1 to 221±40.4 nmol per hour per milligram of protein (Table 2Table 2
α-Galactosidase A Activity in Lymphocytes and Endomyocardial Cells before and after the Initiation of Treatment with Intravenous Galactose.). Similarly, the mean α-galactosidase A activity in endomyocardial-biopsy specimens increased from 50.4±5.3 to 140±1.5 nmol per hour per milligram of protein. On the basis of these results, treatment with galactose infusions (1 g per kilogram, given over a four-hour period every other day) was initiated. The effects of this regimen on cardiac function and endomyocardial glycosphingolipid deposition were evaluated after three months and then periodically during treatment.The galactose infusions were well tolerated, and the results of liver-function tests performed every 90 days were normal during the first 2 years of treatment and have remained normal. After three months, electrocardiography and Holter-monitoring studies revealed a decrease in the heart rate at rest (mean, from 95 to 75 beats per minute) and during exercise (mean, from 160 to 120 beats per minute), with moderate improvement in the ST-T–wave changes. The frequency of ventricular ectopic beats was reduced from 12,720 per 24 hours to 562 per 24 hours, with no evidence of couplets or triplets. The QRS voltages remained unchanged. A two-dimensional Doppler echocardiographic study performed at three months showed improvement in cardiac contractility (left ventricular ejection fraction, 55 percent) and a reduction in myocardial-wall thicknesses (interventricular septum, 16 mm; left ventricular posterior wall, 14 mm) (Table 1).
MRI, performed with a 1.5-T scanner in the same planes and with the same sequences as in the pretreatment studies, revealed moderate reductions in the mean left-ventricular-wall and right-ventricular-wall thicknesses (15 mm and 7 mm, respectively), normal left ventricular diameters, and an improvement in left ventricular global function (left ventricular ejection fraction, 51 percent) (Table 1). The mass of the left ventricle decreased about 20 percent, to 235 g. No other left ventricular regional abnormalities were evident.
The patient's NYHA functional status improved from class IV to class I, and he was able to perform activities involving moderate effort without chest pain or dyspnea. After two years of continuous treatment with a galactose infusion every other day, the improvement in the patient's cardiac function was maintained, as indicated by the results of the two-dimensional echocardiographic and cardiac cine MRI studies (Table 1). MRI showed that the mean thicknesses of the left ventricular and right ventricular walls were 14.5 mm and 6.5 mm, respectively; the left ventricular ejection fraction was 55 percent.
The area of the endomyocardial storage vacuoles decreased with galactose treatment (Figure 1B, Figure 2C, and Figure 2D and Table 3Table 3
Morphometric Analysis of Endomyocardial-Biopsy Specimens before Treatment with Intravenous Galactose and after 90 Days.). Morphometric analysis of the left ventricular and right ventricular endomyocardial tissues after three months of treatment showed decreases in the mean vacuolar area, from 61±8.9 percent to 22±4.7 percent and from 35±7.1 percent to 26±5.7 percent of the total cell area, respectively. No significant variation of the long and short axes of the myocardial cells was seen after three months of treatment (Table 3). These microscopical observations were consistent with the macroscopical values measured by MRI and two-dimensional Doppler echocardiography.Discussion
Although the causes of many types of cardiomyopathy have recently been clarified (among them genetic, inflammatory, and autoimmune disorders17-19), treatment is still a major challenge. Of the various types of cardiomyopathy, the cardiac variant of Fabry's disease may be more common than previously believed; in one study it was diagnosed in 3 percent of unselected men with left ventricular hypertrophy,20 and in another it was diagnosed in 9 percent of male patients with hypertrophic nonobstructive cardiomyopathy.21 In the cardiac variant of Fabry's disease, residual α-galactosidase A activity prevents the characteristic manifestations of the classic disease, which are due to involvement of the vascular endothelium of the heart, kidney, or brain. Patients with the cardiac variant have little if any vascular involvement, and cardiac symptoms develop late in life.
The finding that galactose and other competitive inhibitors of α-galactosidase A can increase or stabilize the activity of the residual mutant α-galactosidase A in cultured cells from patients with the cardiac variant of Fabry's disease5,9,22 suggested that intravenous galactose may enter the cells and increase the stability and activity of the residual enzyme. This was the reasoning behind the trial of galactose therapy in our patient, whose lymphocytes retained α-galactosidase A enzymatic activity at about 7 percent of the level of activity in normal lymphocytes.
After we observed that three daily galactose infusions increased α-galactosidase A activity in his circulating lymphocytes and endomyocardial cells, the patient received galactose infusions every other day for two years, and he continues to receive them. Not only were the infusions well tolerated, but marked improvement in cardiac contractility (seen as an increase in the left ventricular ejection fraction from 33 percent to 55 percent), a moderate reduction in ventricular-wall thickness, and a 20 percent reduction in cardiac mass were documented after three months of treatment. These improvements, which have persisted for more than two years, were confirmed by the findings of independent observers, by two-dimensional echocardiography, and by cardiac MRI studies. Cardiac transplantation was no longer required in this patient, because of the clinical improvement (from NYHA functional class IV to class I) during galactose-infusion therapy. The patient has returned to full-time work as a bus driver.
The mechanism by which galactose and other reversible competitive inhibitors enhance the activity and stability of mutant α-galactosidase A has been the subject of recent studies.9,10 The substrates of wild-type α-galactosidase A are neutral glycosphingolipids with terminal α-galactosyl residues. Galactose and other reversible competitive inhibitors of the enzyme act as “chemical chaperones”23,24 that enhance the stability of the mutant enzyme by binding to its active sites (Figure 3Figure 3
Proposed Mechanism of Enzyme Stabilization by Chemical Chaperones.). In this way, the chaperones promote the proper folding, dimerization, and processing of the enzyme, thereby preventing the proteasomal degradation of misfolded, mutant enzymes. The stabilized enzyme is transported through the Golgi apparatus to lysosomes, where it may be even more stable, because of the acidic environment of those organelles (Figure 3). In the lysosome, accumulated glycosphingolipid (the usual substrate of α-galactosidase A) has a much higher affinity for the active site of the enzyme than galactose. As a result, it displaces galactose from the active site and becomes susceptible to degradation by enzymatic hydrolysis.Studies of different mutant α-galactosidase A enzymes have shown that the residual enzymatic activity encoded by two other mutations in the cardiac variant of Fabry's disease — one encoding the substitution of glutamic acid for glutamine at position 279 (Q279E) and one encoding the substitution of glutamine for arginine at position 301 (R301Q) — is markedly increased by galactose22 and 1-deoxygalactonojirimycin (another reversible competitive inhibitor of the enzyme),9,10 whereas the activity of the G328R mutant enzyme is minimally enhanced. Such in vitro experiments may be used to predict which patients with the cardiac variant of Fabry's disease (or even the classic disease) will benefit from galactose therapy.
Of the more than 160 mutations described in unrelated patients with Fabry's disease,2 a mutation encoding the substitution of histidine for arginine at position 112 (R112H), R301Q, and G328R have been identified in patients with either the classic phenotype or the cardiac-variant phenotype.25-28 These missense mutations presumably allow extremely low levels of residual activity that can be stabilized by certain substrates.
For patients with classic Fabry's disease, enzyme replacement appears efficacious.29,30 For patients with the cardiac variant whose residual α-galactosidase A activity can be enhanced in vitro, chaperone-mediated therapy with galactose or other inhibitors may prove safe and therapeutically effective, as in our patient. Patients with unexplained left ventricular hypertrophy or hypertrophic nonobstructive cardiomyopathy should be evaluated for Fabry's disease by means of assays of their plasma α-galactosidase A activity, and those with residual α-galactosidase A activity that increases in response to an initial trial of galactose supplementation in vitro should be considered for treatment with a nontoxic, reversible competitive inhibitor such as galactose, at least until enzyme-replacement therapy or gene therapy31 proves efficacious. Our study supports the use of chaperone-mediated therapy for late-onset lysosomal storage diseases and possibly other genetic disorders.2,9
Supported in part by grants from the National Institutes of Health, including a Merit Award (R37 DK34045), a grant (MO1 RR00071) from the National Center for Research Resources to the Mount Sinai General Clinical Research Center, and a grant (P30 HD28822) to the Mount Sinai Child Health Research Center, and by a research grant from Genzyme Corporation.
We are indebted to Attilio Maseri, who guides our group in clinical research and medicine and who mentors us in the philosophy of research.
Source Information
From the Departments of Cardiology (A.F., C.C., M.P.), Pediatrics (R.R.), and Radiology (L.N.), Università Cattolica del Sacro Cuore, Rome; the Department of Medicina Sperimentale e Patologia, Università La Sapienza, Rome (M.A.R.); and the Department of Human Genetics, Mount Sinai School of Medicine, New York (C.M.E., R.J.D.).
Address reprint requests to Dr. Desnick at the Department of Human Genetics, Box 1498, Mount Sinai School of Medicine, 5th Ave. at 100th St., New York, NY 10029, or at rjd.fabry@mssm.edu.
- References
References
1
Desnick RJ, Ioannou YA, Eng CM. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic and molecular bases of inherited disease. 7th ed. Vol. 2. New York: McGraw-Hill, 1995:2741-84.
2
Idem. α-Galactosidase A deficiency: Fabry disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The metabolic & molecular bases of inherited disease. 8th ed. Vol. 3. New York: McGraw-Hill, 2001:3733-74.
3
von Scheidt W ,Eng CM ,Fitzmaurice TF , et al. An atypical variant of Fabry's disease with manifestations confined to the myocardium. N Engl J Med 1991;324:395-399
Full Text | Web of Science | Medline4
Elleder M ,Dorazilova V ,Bradova V , et al. Fabry's disease with isolated disease of the cardiac muscle, manifesting as hypertrophic cardiomyopathy. Cas Lek Cesk 1990;129:369-372
Medline5
Ishii S ,Kase R ,Sakuraba H ,Suzuki Y . Characterization of a mutant α-galactosidase gene product for the late-onset cardiac form of Fabry disease. Biochem Biophys Res Commun 1993;197:1585-1589
CrossRef | Web of Science | Medline6
Nagao Y ,Nakashima H ,Fukuhara Y , et al. Hypertrophic cardiomyopathy in late-onset variant of Fabry disease with high residual activity of α-galactosidase A. Clin Genet 1991;39:233-237
CrossRef | Web of Science | Medline7
Eng CM ,Guffon N ,Wilcox WR , et al. Safety and efficacy of recombinant human α-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001;345:9-16
Full Text | Web of Science | Medline8
Okumiya T ,Ishii S ,Takenaka T , et al. Galactose stabilizes various missense mutants of α-galactosidase in Fabry disease. Biochem Biophys Res Commun 1995;214:1219-1224
CrossRef | Web of Science | Medline9
Fan JQ ,Ishii S ,Asano N ,Suzuki Y . Accelerated transport and maturation of lysosomal α-galactosidase A in Fabry lymphoblasts by an enzyme inhibitor. Nat Med 1999;5:112-115
CrossRef | Web of Science | Medline10
Asano N ,Ishii S ,Kizu H , et al. In vitro inhibition and intracellular enhancement of lysosomal α-galactosidase A activity in Fabry lymphoblasts by 1-deoxygalactonojirimycin and its derivatives. Eur J Biochem 2000;267:4179-4186
CrossRef | Medline11
Elleder M ,Bradova V ,Smid F , et al. Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease: report on a case simulating hypertrophic non-obstructive cardiomyopathy. Virchows Arch A Pathol Anat Histopathol 1990;417:449-455
CrossRef | Medline12
Miller PJ . An elastin stain. Med Lab Technol 1971;28:148-149
Medline13
Boyum A . Isolation of leucocytes from human blood: a two-phase system for removal of red cells with methylcellulose as erythrocyte-aggregating agent. Scand J Clin Lab Invest Suppl 1968;97:9-29
Medline14
Hall CW ,Liebaers I ,Di Natale P ,Neufeld EF . Enzymatic diagnosis of the genetic mucopolysaccharide storage disorders. Methods Enzymol 1978;50:439-456
CrossRef | Medline15
Desnick RJ ,Allen KY ,Desnick SJ ,Raman MK ,Bernlohr RW ,Krivit W . Fabry's disease: enzymatic diagnosis of hemizygotes and heterozygotes: α-galactosidase activities in plasma, serum, urine, and leukocytes. J Lab Clin Med 1973;81:157-171
Medline16
Eng CM ,Resnick-Silverman LA ,Niehaus DJ ,Astrin KH ,Desnick RJ . Nature and frequency of mutations in the α-galactosidase A gene that cause Fabry disease. Am J Hum Genet 1993;53:1186-1197
Web of Science | Medline17
Bonne G ,Carrier L ,Richard P ,Hainque B ,Schwartz K . Familial hypertrophic cardiomyopathy: from mutations to functional defects. Circ Res 1998;83:580-593
Web of Science | Medline18
Kamisago M ,Sharma SD ,DePalma SR , et al. Mutations in sarcomere protein genes as a cause of dilated cardiomyopathy. N Engl J Med 2000;343:1688-1696
Full Text | Web of Science | Medline19
Towbin JA ,Bowles NE . Genetic abnormalities responsible for dilated cardiomyopathy. Curr Cardiol Rep 2000;2:475-480
CrossRef | Medline20
Nakao S ,Takenaka T ,Maeda M , et al. An atypical variant of Fabry's disease in men with left ventricular hypertrophy. N Engl J Med 1995;333:288-293
Full Text | Web of Science | Medline21
Kuhn H ,Kohler E ,Hort W ,Frenzel H . Concealed myocardial storage disease (Fabry's disease): pitfalls in the diagnosis of hypertrophic non obstructive cardiomyopathy. Circulation 1982;66:Suppl II:II-117 abstract.22
Okumiya T ,Ishii S ,Kase R ,Kamei S ,Sakuraba H ,Suzuki Y . α-Galactosidase gene mutations in Fabry disease: heterogeneous expressions of mutant enzyme proteins. Hum Genet 1995;95:557-561
CrossRef | Web of Science | Medline23
Kuznetsov G ,Nigam SK . Folding of secretory and membrane proteins. N Engl J Med 1998;339:1688-1695
Full Text | Web of Science | Medline24
McClellan AJ ,Frydman J . Molecular chaperones and the art of recognizing a lost cause. Nat Cell Biol 2001;3:E51-E53
CrossRef | Web of Science | Medline25
Ishii S ,Kase R ,Sakuraba H , et al. Human α-galactosidase gene expression: significance of two peptide regions encoded by exons 1-2 and 6. Biochim Biophys Acta 1994;1204:265-270
CrossRef | Web of Science | Medline26
Ashton-Prolla P ,Tong B ,Shabbeer J ,Astrin KH ,Eng CM ,Desnick RJ . Fabry disease: twenty-two novel mutations in the α-galactosidase A gene and genotype/phenotype correlations in severely and mildly affected hemizygotes and heterozygotes. J Investig Med 2000;48:227-235
Web of Science | Medline27
Eng CM ,Niehaus DJ ,Enriquez AL ,Burgert TS ,Ludman MD ,Desnick RJ . Fabry disease: twenty-three mutations including sense and antisense CpG alterations and identification of a deletion hot-spot in the α-galactosidase A gene. Hum Mol Genet 1994;3:1795-1799
CrossRef | Web of Science | Medline28
Sakuraba H ,Oshima A ,Fukuhara Y , et al. Identification of point mutations in the α-galactosidase A gene in classical and atypical hemizygotes with Fabry disease. Am J Hum Genet 1990;47:784-789
Web of Science | Medline29
Eng CM ,Banikazemi M ,Gordon RE , et al. A phase 1/2 clinical trial of enzyme replacement in Fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001;68:711-722
CrossRef | Web of Science | Medline30
Schiffmann R ,Kopp JB ,Austin H , et al. Efficacy and safety of enzyme replacement therapy for Fabry disease demonstrated by a double-blind placebo-controlled trial. Am J Hum Genet 2000;67:Suppl 2:38-38 abstract.
Web of Science31
Zeigler RJ ,Yew NS ,Li C , et al. Correction of enzymatic and lysosomal storage defects in Fabry mice by adenovirus-mediated gene transfer. Hum Gene Ther 1999;10:1667-1682
CrossRef | Web of Science | Medline
- Citing Articles (111)
Citing Articles
1
Satoshi ISHII. (2012) Pharmacological chaperone therapy for Fabry disease. Proceedings of the Japan Academy, Series B 88:1, 18-30
CrossRef2
Ornella Leone, John P. Veinot, Annalisa Angelini, Ulrik T. Baandrup, Cristina Basso, Gerald Berry, Patrick Bruneval, Margaret Burke, Jagdish Butany, Fiorella Calabrese, Giulia d'Amati, William D. Edwards, John T. Fallon, Michael C. Fishbein, Patrick J. Gallagher, Marc K. Halushka, Bruce McManus, Angela Pucci, E. René Rodriguez, Jeffrey E. Saffitz, Mary N. Sheppard, Charles Steenbergen, James R. Stone, Carmela Tan, Gaetano Thiene, Allard C. van der Wal, Gayle L. Winters. (2011) 2011 Consensus statement on endomyocardial biopsy from the Association for European Cardiovascular Pathology and the Society for Cardiovascular Pathology. Cardiovascular Pathology
CrossRef3
Abigail I. Guce, Nathaniel E. Clark, Jerome J. Rogich, Scott C. Garman. (2011) The Molecular Basis of Pharmacological Chaperoning in Human α-Galactosidase. Chemistry & Biology 18:12, 1521-1526
CrossRef4
A. M. From, J. J. Maleszewski, C. S. Rihal. (2011) Current Status of Endomyocardial Biopsy. Mayo Clinic Proceedings 86:11, 1095-1102
CrossRef5
John P. Veinot. (2011) Endomyocardial biopsy—when and how?. Cardiovascular Pathology 20:5, 291-296
CrossRef6
Charles Masson. (2011) Maladie de Fabry : une maladie du métabolisme par déficit d’une enzyme lysosomale (alpha-galactosidase), de transmission héréditaire liée au chromosome X accessible au traitement enzymatique de substitution. Revue du Rhumatisme Monographies 78:4, 262-266
CrossRef7
Mouaz H. Al-Mallah, Mohammad Naseem Shareef. (2011) The role of cardiac magnetic resonance imaging in the assessment of non-ischemic cardiomyopathy. Heart Failure Reviews 16:4, 369-380
CrossRef8
Matjaž Kopač, Anamarija Meglič, Rina R Rus. (2011) Partial Remission of Resistant Nephrotic Syndrome After Oral Galactose Therapy. Therapeutic Apheresis and Dialysis 15:3, 269-272
CrossRef9
Kenneth J. Valenzano, Richie Khanna, Allan C. Powe, Robert Boyd, Gary Lee, John J. Flanagan, Elfrida R. Benjamin. (2011) Identification and Characterization of Pharmacological Chaperones to Correct Enzyme Deficiencies in Lysosomal Storage Disorders. ASSAY and Drug Development Technologies 9:3, 213-235
CrossRef10
L Ferri, C Guido, G la Marca, S Malvagia, C Cavicchi, A Fiumara, R Barone, R Parini, D Antuzzi, C Feliciani, A Zampetti, R Manna, S Giglio, CM Della Valle, X Wu, KJ Valenzano, ER Benjamin, MA Donati, R Guerrini, M Genuardi, A Morrone. (2011) Fabry disease: polymorphic haplotypes and a novel missense mutation in the GLA gene. Clinical Geneticsno-no
CrossRef11
Haruhiko Higashi, Kenichiro Yamagata, Takashi Noda, Kazuhiro Satomi. (2011) Endocardial and epicardial substrates of ventricular tachycardia in a patient with Fabry disease. Heart Rhythm 8:1, 133-136
CrossRef12
Scott E. Kasner, Brett L. Cucchiara. 2011. Treatment of “Other” Stroke Etiologies. , 1084-1105.
CrossRef13
Kenneth J. Valenzano, Elfrida R. Benjamin, Patricia René, Michel Bouvier. 2010. Pharmacological Chaperones: Potential for the Treatment of Hereditary Diseases Caused by Mutations in G Protein-Coupled Receptors. , 460-510.
CrossRef14
M Rajappa, A Goyal, J Kaur. (2010) Inherited metabolic disorders involving the eye: a clinico-biochemical perspective. Eye 24:4, 507-518
CrossRef15
Lionel Batista, Florence Miller, Céline Clave, Audrey Arfi, Gaëlle Douillard-Guilloux, Pierre-Olivier Couraud, Catherine Caillaud. (2010) Induced secretion of β-hexosaminidase by human brain endothelial cells: A novel approach in Sandhoff disease?. Neurobiology of Disease 37:3, 656-660
CrossRef16
Constantinos O'Mahony, Perry Elliott. (2010) Anderson-Fabry Disease and the Heart. Progress in Cardiovascular Diseases 52:4, 326-335
CrossRef17
Theodoros D. Karamitsos, Jane M. Francis, Saul Myerson, Joseph B. Selvanayagam, Stefan Neubauer. (2009) The Role of Cardiovascular Magnetic Resonance Imaging in Heart Failure. Journal of the American College of Cardiology 54:15, 1407-1424
CrossRef18
E. De Smet, J.-P. Rioux, H. Ammann, C. Deziel, S. Querin. (2009) FSGS permeability factor-associated nephrotic syndrome: remission after oral galactose therapy. Nephrology Dialysis Transplantation 24:9, 2938-2940
CrossRef19
Giancarlo Parenti. (2009) Treating lysosomal storage diseases with pharmacological chaperones: from concept to clinics. EMBO Molecular Medicine 1:5, 268-279
CrossRef20
Bryan G. Winchester. (2009) Iminosugars: from botanical curiosities to licensed drugs. Tetrahedron: Asymmetry 20:6-8, 645-651
CrossRef21
Frances M. Platt, Robin H. Lachmann. (2009) Treating lysosomal storage disorders: Current practice and future prospects. Biochimica et Biophysica Acta (BBA) - Molecular Cell Research 1793:4, 737-745
CrossRef22
Anna Caciotti, Maria Alice Donati, Alessandra d'Azzo, Rosa Salvioli, Renzo Guerrini, Enrico Zammarchi, Amelia Morrone. (2009) The potential action of galactose as a “chemical chaperone”: Increase of beta galactosidase activity in fibroblasts from an adult GM1-gangliosidosis patient. European Journal of Paediatric Neurology 13:2, 160-164
CrossRef23
John P. Veinot. (2009) Diagnostic endomyocardial biopsy – still useful after all these years. Canadian Journal of Cardiology 25:2, e55-e56
CrossRef24
Jung-Young Park, Gu-Hwan Kim, Sung-Su Kim, Jung Min Ko, Jin-Joo Lee, Han-Wook Yoo. (2009) Effects of a chemical chaperone on genetic mutations in α-galactosidase A in Korean patients with Fabry disease. Experimental and Molecular Medicine 41:1, 1
CrossRef25
Bredy Pierre-Louis, Anil Kumar, William H. Frishman. (2009) Fabry Disease. Cardiology in Review 17:1, 31-35
CrossRef26
Camilla Filoni, Anna Caciotti, Laura Carraresi, Maria Alice Donati, Renzo Mignani, Rossella Parini, Mirella Filocamo, Fausto Soliani, Lisa Simi, Renzo Guerrini, Enrico Zammarchi, Amelia Morrone. (2008) Unbalanced GLA mRNAs ratio quantified by real-time PCR in Fabry patients' fibroblasts results in Fabry disease. European Journal of Human Genetics 16:11, 1311-1317
CrossRef27
Yuri A Zarate, Robert J Hopkin. (2008) Fabry's disease. The Lancet 372:9647, 1427-1435
CrossRef28
Kanako Sugawara, Kazuki Ohno, Seiji Saito, Hitoshi Sakuraba. (2008) Structural characterization of mutant α-galactosidases causing Fabry disease. Journal of Human Genetics 53:9, 812-824
CrossRef29
Virginia J. Savin, Ellen T. McCarthy, Ram Sharma, Deane Charba, Mukut Sharma. (2008) Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity. Translational Research 151:6, 288-292
CrossRef30
Cristina Chimenti, Nazha Hamdani, Nicky M. Boontje, Francesco DeCobelli, Antonio Esposito, Jean G.F. Bronzwaer, Ger J.M. Stienen, Matteo A. Russo, Walter J. Paulus, Andrea Frustaci, Jolanda van der Velden. (2008) Myofilament Degradation and Dysfunction of Human Cardiomyocytes in Fabry Disease. The American Journal of Pathology 172:6, 1482-1490
CrossRef31
ARASH ARYANA, MICHAEL A. FIFER, JEREMY N. RUSKIN, THEOFANIE MELA. (2008) Short PR Interval in the Absence of Preexcitation: A Characteristic Finding in a Patient with Fabry Disease. Pacing and Clinical Electrophysiology 31:6, 782-783
CrossRef32
S. B. Joshi, W. Ahmar, G. Lee, A. Aggarwal. (2008) Fabry's disease presenting as ventricular tachycardia and Left Ventricular 'Hypertrophy'. European Journal of Echocardiography 9:5, 697-699
CrossRef33
Melissa P Wasserstein, Margaret M McGovern. (2008) Genetic basis of the lipid storage disorders. Future Lipidology 3:2, 189-201
CrossRef34
Jian-Qiang Fan. (2008) A counterintuitive approach to treat enzyme deficiencies: use of enzyme inhibitors for restoring mutant enzyme activity. Biological Chemistry 389:1, 1-11
CrossRef35
CRAIG R. ASHER, ALLAN L. KLEIN. 2008. Primary Restrictive, Infiltrative, and Storage Cardiomyopathies. , 259-276.
CrossRef36
J. Malcolm O. Arnold, Jonathan G. Howlett, Anique Ducharme, Justin A. Ezekowitz, Martin J. Gardner, Nadia Giannetti, Haissam Haddad, George A. Heckman, Debra Isaac, Philip Jong, Peter Liu, Elizabeth Mann, Robert S. McKelvie, Gordon W. Moe, Anna M. Svendsen, Ross T. Tsuyuki, Kelly O’Halloran, Heather J. Ross, Errol J. Sequeira, Michel White. (2008) Canadian Cardiovascular Society Consensus Conference guidelines on heart failure – 2008 update: Best practices for the transition of care of heart failure patients, and the recognition, investigation and treatment of cardiomyopathies. Canadian Journal of Cardiology 24:1, 21-40
CrossRef37
Yoshiyuki Suzuki, Satoshi Ichinomiya, Mieko Kurosawa, Masato Ohkubo, Hiroshi Watanabe, Hiroyuki Iwasaki, Junichiro Matsuda, Yoko Noguchi, Kazuhiro Takimoto, Masayuki Itoh, Miho Tabe, Masami Iida, Takatoshi Kubo, Seiichiro Ogawa, Eiji Nanba, Katsumi Higaki, Kousaku Ohno, Roscoe O. Brady. (2007) Chemical chaperone therapy: clinical effect in murine G M1 -gangliosidosis. Annals of Neurology 62:6, 671-675
CrossRef38
Leslie T. Cooper, Kenneth L. Baughman, Arthur M. Feldman, Andrea Frustaci, Mariell Jessup, Uwe Kuhl, Glenn N. Levine, Jagat Narula, Randall C. Starling, Jeffrey Towbin, Renu Virmani. (2007) The Role of Endomyocardial Biopsy in the Management of Cardiovascular Disease. Journal of the American College of Cardiology 50:19, 1914-1931
CrossRef39
Zhanqian Yu, Anu R. Sawkar, Jeffery W. Kelly. (2007) MINIREVIEW: Pharmacologic chaperoning as a strategy to treat Gaucher disease. FEBS Journal 274:19, 4944-4950
CrossRef40
Jian-Qiang Fan, Satoshi Ishii. (2007) MINIREVIEW: Active-site-specific chaperone therapy for Fabry disease. FEBS Journal 274:19, 4962-4971
CrossRef41
Sang-Hoon Shin, Gary J. Murray, Stefanie Kluepfel-Stahl, Adele M. Cooney, Jane M. Quirk, Raphael Schiffmann, Roscoe O. Brady, Christine R. Kaneski. (2007) Screening for pharmacological chaperones in Fabry disease. Biochemical and Biophysical Research Communications 359:1, 168-173
CrossRef42
Rangadham Nagarakanti, David Whellan, Sharon Rubin, Paul J. Mather. (2007) Reversible Cardiomyopathies. Cardiology in Review 15:4, 178-183
CrossRef43
Carla EM Hollak, Anouk C Vedder, Gabor E Linthorst, Johannes MFG Aerts. (2007) Novel therapeutic targets for the treatment of Fabry disease. Expert Opinion on Therapeutic Targets 11:6, 821-833
CrossRef44
Éva Rákóczi, Sándor Görögh, János Grubits, Melinda Erdős, Ferenc Garzuly, Katalin Hahn, Krisztina Bencsik, László Vécsei, Csilla Trinn, Éva Kristóf, Gábor Mogyorósy, Beáta Tóth, László Maródi. (2007) A Fabry-kór molekuláris patológiája és klinikai megjelenési formái. Orvosi Hetilap 148:23, 1087-1094
CrossRef45
Tip W. Loo, David M. Clarke. (2007) Chemical and pharmacological chaperones as new therapeutic agents. Expert Reviews in Molecular Medicine 9:16,
CrossRef46
David H. Perlmutter, Jeffrey L. Brodsky, William F. Balistreri, Bruce C. Trapnell. (2007) Molecular pathogenesis of alpha-1-antitrypsin deficiency-associated liver disease: A meeting review. Hepatology 45:5, 1313-1323
CrossRef47
Christian Weirich, Douglas R. Keene, Katja Kirsch, Matthias Heil, Elena Neumann, Robert Dinser. (2007) Expression of PSACH-associated mutant COMP in tendon fibroblasts leads to increased apoptotic cell death irrespective of the secretory characteristics of mutant COMP. Matrix Biology 26:4, 314-323
CrossRef48
J Edmond Wraith. (2007) Idursulfase for enzyme-replacement therapy in mucopolysaccharidosis II. Therapy 4:3, 231-240
CrossRef49
Giancarlo Parenti, Alfredo Zuppaldi, M Gabriela Pittis, M Rosaria Tuzzi, Ida Annunziata, Germana Meroni, Caterina Porto, Francesca Donaudy, Barbara Rossi, Massimiliano Rossi, Mirella Filocamo, Alice Donati, Bruno Bembi, Andrea Ballabio, Generoso Andria. (2007) Pharmacological Enhancement of Mutated α-Glucosidase Activity in Fibroblasts from Patients with Pompe Disease. Molecular Therapy 15:3, 508-514
CrossRef50
Toshika Okumiya, Marian A. Kroos, Laura Van Vliet, Hiroaki Takeuchi, Ans T. Van der Ploeg, Arnold J.J. Reuser. (2007) Chemical chaperones improve transport and enhance stability of mutant α-glucosidases in glycogen storage disease type II. Molecular Genetics and Metabolism 90:1, 49-57
CrossRef51
David G. Warnock. (2007) Enzyme Replacement Therapy and Fabry Kidney Disease. Clinical Therapeutics 29, S96-S98
CrossRef52
Franco Cecchi, Anna Frullini, Iacopo Olivotto, Gabriele Castelli, Mauro Ciaccheri, Fabrizio Martinelli, Francesca Torricelli, Walter Borsini, Francesca Garbini. (2007) Hypertrophic Cardiomyopathy in Anderson-Fabry Disease. Clinical Therapeutics 29, S93-S94
CrossRef53
Tsutomu Arakawa, Daisuke Ejima, Yoshiko Kita, Kouhei Tsumoto. (2006) Small molecule pharmacological chaperones: From thermodynamic stabilization to pharmaceutical drugs. Biochimica et Biophysica Acta (BBA) - Proteins & Proteomics 1764:11, 1677-1687
CrossRef54
M. Pauschinger, M. Noutsias, D. Lassner, H.-P. Schultheiss, U. Kuehl. (2006) Inflammation, ECG changes and pericardial effusion. Clinical Research in Cardiology 95:11, 569-583
CrossRef55
H IWASAKI, H WATANABE, M IIDA, S OGAWA, M TABE, K HIGAKI, E NANBA, Y SUZUKI. (2006) Fibroblast screening for chaperone therapy in β-galactosidosis. Brain and Development 28:8, 482-486
CrossRef56
Marco Spada, Severo Pagliardini, Makiko Yasuda, Turgut Tukel, Geetha Thiagarajan, Hitoshi Sakuraba, Alberto Ponzone, Robert J. Desnick. (2006) High Incidence of Later-Onset Fabry Disease Revealed by Newborn Screening*. The American Journal of Human Genetics 79:1, 31-40
CrossRef57
David G. Warnock, Michael L. West. (2006) Diagnosis and Management of Kidney Involvement in Fabry Disease. Advances in Chronic Kidney Disease 13:2, 138-147
CrossRef58
Yoshiyuki Suzuki. (2006) β-Galactosidase deficiency: An approach to chaperone therapy. Journal of Inherited Metabolic Disease 29:2-3, 471-476
CrossRef59
Maurizio Pieroni, Cristina Chimenti, Francesco De Cobelli, Emanuela Morgante, Alessandro Del Maschio, Carlo Gaudio, Matteo Antonio Russo, Andrea Frustaci. (2006) Fabry’s Disease Cardiomyopathy. Journal of the American College of Cardiology 47:8, 1663-1671
CrossRef60
Jun-Chao WU, Zhong-Qin LIANG, Zheng-Hong QIN. (2006) Quality Control System of the Endoplasmic Reticulum and Related Diseases. Acta Biochimica et Biophysica Sinica 38:4, 219-226
CrossRef61
Louis J. Elsas. (2006) The history of the SIMD: From small molecules to metabolomics. Molecular Genetics and Metabolism 87:3, 204-209
CrossRef62
R. J. Kalliokoski, I. Kantola, K. K. Kalliokoski, E. Engblom, J. Sundell, J. C. Hannukainen, T. Janatuinen, O. T. Raitakari, J. Knuuti, M. Penttinen, J. Viikari, P. Nuutila. (2006) The effect of 12-month enzyme replacement therapy on myocardial perfusion in patients with Fabry disease. Journal of Inherited Metabolic Disease 29:1, 112-118
CrossRef63
Paul D Maher, Marlene Haffner. (2006) Orphan Drug Designation and Pharmacogenomics. BioDrugs 20:2, 71-79
CrossRef64
H.-P. Schultheiss, M. Noutsias, U. Kühl, U. Gross, D. Lassner, W. Poller, M. Pauschinger. (2005) Kardiomyopathien. Der Internist 46:12, 1373-1388
CrossRef65
Gregory M Pastores, Natalie L Barnett. (2005) Current and emerging therapies for the lysosomal storage disorders. Expert Opinion on Emerging Drugs 10:4, 891-902
CrossRef66
OSAMU IGAWA, JUNICHIRO MIAKE, ICHIRO HISATOME. (2005) Ventricular Tachycardias and Dilated Cardiomyopathy Caused by Fabry Disease. Pacing and Clinical Electrophysiology 28:10, 1142-1143
CrossRef67
Giancarlo Goi, Luca Massaccesi, Alessandro P. Burlina, Claudia J. Baquero Herrera, Adriana Lombardo, Guido Tettamanti, Alberto B. Burlina. (2005) Lysosomal leukocyte β-d-glucuronidase during enzyme replacement therapy in Fabry disease. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1741:3, 300-306
CrossRef68
Fumiko Matsuzawa, Sei-ichi Aikawa, Hirofumi Doi, Toshika Okumiya, Hitoshi Sakuraba. (2005) Fabry disease: correlation between structural changes in α-galactosidase, and clinical and biochemical phenotypes. Human Genetics 117:4, 317-328
CrossRef69
Mylvaganam Jeyakumar, Raymond A. Dwek, Terry D. Butters, Frances M. Platt. (2005) Storage solutions: treating lysosomal disorders of the brain. Nature Reviews Neuroscience
CrossRef70
J Shah, P Elliott. (2005) Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy. Acta Paediatrica 94:0, 11-14
CrossRef71
JS Shah, PM Elliott. (2005) Fabry disease and the heart: an overview of the natural history and the effect of enzyme replacement therapy. Acta Paediatrica 94, 11-14
CrossRef72
Ashok Vellodi. (2005) Lysosomal storage disorders. British Journal of Haematology 128:4, 413-431
CrossRef73
E. Mahé, S. Hadj-Rabia, D. Chauveau, Y. De Prost. (2005) Maladie de Fabry - Place du dermatologue et progrès thérapeutiques. Annales de Dermatologie et de Vénéréologie 132:2, 171-176
CrossRef74
(2005) Angiokeratomas, Fabry disease and enzyme replacement therapy: still a challenge. British Journal of Dermatology 152:1, 177-178
CrossRef75
Gregory Bierer, Nader Kamangar, David Balfe, William R. Wilcox, Zab Mosenifar. (2005) Cardiopulmonary Exercise Testing in Fabry Disease. Respiration 72:5, 504-511
CrossRef76
Catherine Caillaud. 2004. Fabry Disease. , 414-418.
CrossRef77
Hatice Asuman Özkara. (2004) Recent advances in the biochemistry and genetics of sphingolipidoses. Brain and Development 26:8, 497-505
CrossRef78
Karin Römisch. (2004) A Cure for Traffic Jams: Small Molecule Chaperones in the Endoplasmic Reticulum. Traffic 5:11, 815-820
CrossRef79
Charles Masson, Idrissa Cissé, Virginie Simon, Paolo Insalaco, Maurice Audran. (2004) Fabry disease: a review. Joint Bone Spine 71:5, 381-383
CrossRef80
Maurizio Pieroni, Cristina Chimenti, Andrea Russo, Matteo Antonio Russo, Attilio Maseri, Andrea Frustaci. (2004) Tissue Doppler imaging in Fabry disease. Current Opinion in Cardiology 19:5, 452-457
CrossRef81
L Spinelli, A Pisani, M Sabbatini, M Petretta, MV Andreucci, D Procaccini, N Lo Surdo, S Federico, B Cianciaruso. (2004) Enzyme replacement therapy with agalsidase β improves cardiac involvement in Fabry's disease. Clinical Genetics 66:2, 158-165
CrossRef82
M. Mohrenschlager, H. V. Henkel, J. Ring. (2004) Fabry outcome survey: need for documentation of dermatological, ophthalmological and psychiatric affections. European Journal of Clinical Investigation 34:7, 515-516
CrossRef83
Virginie Bernier, Monique Lagacé, Daniel G Bichet, Michel Bouvier. (2004) Pharmacological chaperones: potential treatment for conformational diseases. Trends in Endocrinology & Metabolism 15:5, 222-228
CrossRef84
A. C. Hauser, M. Lorenz, G. Sunder-Plassmann. (2004) The expanding clinical spectrum of Anderson-Fabry disease: a challenge to diagnosis in the novel era of enzyme replacement therapy. Journal of Internal Medicine 255:6, 629-636
CrossRef85
S E Hughes. (2004) The pathology of hypertrophic cardiomyopathy. Histopathology 44:5, 412-427
CrossRef86
Aamer H. Jamali, Riaz M. Ahmed, Herbert Stein. (2004) An Unusual Cause of Dyspnea. Cardiology in Review 12:1, 10-14
CrossRef87
Scott E. Kasner. 2004. Treatment of "Other" Causes of Stroke. , 1059-1077.
CrossRef88
Frank Breunig, Anita Knoll, Christoph Wanner. (2003) Enzyme replacement therapy in Fabry disease: clinical implications. Current Opinion in Nephrology and Hypertension 12:5, 491-495
CrossRef89
Shoichiro Nakao, Chihaya Kodama, Toshihiro Takenaka, Akihiro Tanaka, Yuichiro Yasumoto, Aichi Yoshida, Tamotsu Kanzaki, Annette L.D. Enriquez, Christine M. Eng, Hiromitsu Tanaka, Chuwa Tei, Robert J. Desnick. (2003) Fabry disease: Detection of undiagnosed hemodialysis patients and identification of a "renal variant" phenotype1. Kidney International 64:3, 801-807
CrossRef90
Gregory M Pastores. (2003) Enzyme therapy for the lysosomal storage disorders: principles, patents, practice and prospects. Expert Opinion on Therapeutic Patents 13:8, 1157-1172
CrossRef91
Matthias Mohrenschlager, Johannes Ring, Dietrich Abeck. (2003) Options in the treatment of fabry disease. Pediatric Dermatology 20:4, 373-374
CrossRef92
Jian-Qiang Fan. (2003) A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends in Pharmacological Sciences 24:7, 355-360
CrossRef93
Robert J. Hopkin, John Bissler, and Gregory A. Grabowski. (2003) Comparative evaluation of α-galactosidase A infusions for treatment of Fabry disease. Genetics in Medicine 5:3, 144-153
CrossRef94
Thomas Kolter, Michaela Wendeler. (2003) Chemical Chaperones-A New Concept in Drug Research. ChemBioChem 4:4, 260-264
CrossRef95
Matthias Lorenz, Anna-Christina Hauser, Margot Püspök-Schwarz, Peter Kotanko, Ingrid Arias, Herbert Zodl, Reinhard Kramar, Eduard Paschke, Till Voigtländer, Gere Sunder-Plassmann. (2003) Anderson-Fabry disease in Austria. Wiener Klinische Wochenschrift 115:7-8, 235-240
CrossRef96
Jan Nemec, Win-Kuang Shen. (2003) Antiarrhythmic drugs: new agents and evolving concepts. Expert Opinion on Investigational Drugs 12:3, 435-453
CrossRef97
Matthias M??hrenschlager, Markus Braun-Falco, Johannes Ring, Dietrich Abeck. (2003) Fabry Disease. American Journal of Clinical Dermatology 4:3, 189-196
CrossRef98
&NA;. (2003) Alpha-Galactosidase ??? Genzyme General. Drugs in R & D 4:2, 115-118
CrossRef99
Marc C. Patterson. 2003. Fabry's Disease. , 333-335.
CrossRef100
Robert J. Desnick, Edward H. Schuchman. (2002) Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nature Reviews Genetics 3:12, 954-966
CrossRef101
DAVID H. PERLMUTTER. (2002) Chemical Chaperones: A Pharmacological Strategy for Disorders of Protein Folding and Trafficking. Pediatric Research 52:6, 832-836
CrossRef102
A Linhart, S Magage, T Palecek, J Bultas. (2002) Cardiac involvement in Fabry disease. Acta Paediatrica 91, 15-20
CrossRef103
Scott C. Garman, David N. Garboczi. (2002) Structural basis of Fabry disease. Molecular Genetics and Metabolism 77:1-2, 3-11
CrossRef104
Louis J. Elsas, Aimee L. Webb, Sharon D. Langley. (2002) Characterization of a carbohydrate response element regulating the gene for human galactose-1-phosphate uridyltransferase. Molecular Genetics and Metabolism 76:4, 287-296
CrossRef105
Michael Beck. (2002) Agalsidase alfa – a preparation for enzyme replacement therapy in Anderson–Fabry disease. Expert Opinion on Investigational Drugs 11:6, 851-858
CrossRef106
Andrea Frustaci, Maurizio Pieroni, Cristina Chimenti. (2002) Late-onset primary LVH HCM versus cardiac fabry variant. Journal of the American College of Cardiology 39:8, 1405-1406
CrossRef107
Ravi Thadhani, Gregory M Pastores. (2002) Advances in the management of Anderson–Fabry disease:enzyme replacement therapy. Expert Opinion on Biological Therapy 2:3, 325-333
CrossRef108
Scott C Garman, Linda Hannick, Alex Zhu, David N Garboczi. (2002) The 1.9 Å Structure of α-N-Acetylgalactosaminidase. Structure 10:3, 425-434
CrossRef109
Raphael Schiffmann, Roscoe O. Brady. (2002) New Prospects for the Treatment of Lysosomal Storage Diseases. Drugs 62:5, 733-742
CrossRef110
Gahl, William A., . (2001) New Therapies for Fabry's Disease. New England Journal of Medicine 345:1, 55-57
Full Text111
&NA;. (2001) Novel therapies show efficacy in Fabry's disease. Inpharma Weekly &NA;:1296, 8
CrossRef
